Avastin Account Orders Double, Reorder Rate Improves To 80%
This article was originally published in The Pink Sheet Daily
Executive Summary
The number of accounts ordering the oncologic rose from 1,500 to more than 3,000 in the second quarter, with 80% of accounts placing reorders. Genentech says the majority of Avastin's sales come from the front-line setting.
You may also be interested in...
Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
Genentech Avastin Line At Vacaville Facility Gains FDA Approval
Product produced at the Vacaville, Calif. site will start shipping by September, Genentech says. The South San Francisco facility will continue to manufacture Avastin.